» Articles » PMID: 37892677

Complete Blood Count Alterations Prior to the Diagnosis of Colorectal Cancer May Help in the Detection of Synchronous Liver Metastases

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 Oct 28
PMID 37892677
Authors
Affiliations
Soon will be listed here.
Abstract

: Colorectal cancer (CRC) represents 10% of all cancers worldwide with the highest incidence in developed countries; its incidence is also increasing in middle- and low-income countries. Population screening programs facilitate early diagnosis of the disease. When the diagnosis is carried out in advanced stages, approximately 80% of patients with liver metastases (LM) are considered unresectable at the time of diagnosis. In our study, variations in blood counts prior to CRC diagnosis were analyzed to assess whether they could be useful in identifying smaller, more manageable metastases at earlier stages for more effective treatment. : A study was carried out using complete blood counts (CBCs) from CRC patients, obtained from primary health centers and the La Ribera University Hospital within La Ribera Health Department, Valencian Community, Spain, between July 2012 and September 2020. Data from CRC patients who presented synchronous liver metastasis (CRLM) were compared with those with CRC without LM at diagnosis (CRC patients). : Our analysis shows that at least 15 months before CRC diagnosis, a progressive alteration was observed in CBC parameters in both groups. A higher incidence of anemia ( < 0.001) was observed among CRLM patients in the three months prior to CRC diagnosis than in CRC patients showing no LM. : A statistically significant deterioration of CBC was observed in patients with advanced-stage CRC and synchronous or early LM (CRLM) in the three months prior to diagnosis. The primary goal of incorporating CBC variations into predictive models is to identify individuals who are at a greater risk of developing metastatic colon cancer, leading to early diagnosis. Our research improves these models by highlighting a more pronounced and rapid decline in hemoglobin levels among CRLM patients. Identification of metastases at an earlier stage when they are smaller, more manageable, and more amenable to treatment may be a valuable tool to prevent their further progression.

Citing Articles

Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review).

Jin Z, Li Y, Yi H, Wang M, Wang C, Du S Int J Oncol. 2025; 66(3).

PMID: 39950314 PMC: 11844340. DOI: 10.3892/ijo.2025.5728.


Complete blood counts as potential risk factors of early dissemination to liver and lungs in resected colorectal cancer: a retrospective cohort study.

Popeda M, Zok J, Tomasik B, Duchnowska R, Bienkowski M Int J Colorectal Dis. 2025; 40(1):21.

PMID: 39836241 PMC: 11750913. DOI: 10.1007/s00384-024-04802-9.


Rapid detection of liver metastasis risk in colorectal cancer patients through blood test indicators.

Yu Z, Li G, Xu W Front Oncol. 2024; 14:1460136.

PMID: 39324006 PMC: 11422013. DOI: 10.3389/fonc.2024.1460136.


Construction of a nomogram model based on biomarkers for liver metastasis in non-small cell lung cancer.

Zhang T, Zhang Y, Ni Y, Jia X, Li Y, Mao Z Thorac Cancer. 2024; 15(26):1897-1911.

PMID: 39098998 PMC: 11462952. DOI: 10.1111/1759-7714.15417.


Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of Colorectal Cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-EGFR and Anti-VEGF Therapies.

Popovici D, Stanisav C, Sima L, Negru A, Murg S, Carabineanu A Medicina (Kaunas). 2024; 60(6).

PMID: 38929620 PMC: 11205545. DOI: 10.3390/medicina60061003.


References
1.
Hao M, Li H, Wang K, Liu Y, Liang X, Ding L . Predicting metachronous liver metastasis in patients with colorectal cancer: development and assessment of a new nomogram. World J Surg Oncol. 2022; 20(1):80. PMC: 8918281. DOI: 10.1186/s12957-022-02558-6. View

2.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

3.
Islami F, Sauer A, Miller K, Siegel R, Fedewa S, Jacobs E . Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2017; 68(1):31-54. DOI: 10.3322/caac.21440. View

4.
Adam R, Kitano Y . Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019; 3(1):50-56. PMC: 6345652. DOI: 10.1002/ags3.12227. View

5.
Nomura K, Miyagawa S, Harada H, Kitamura H, Seki H, Shimada R . Relationship between doubling time of liver metastases from colorectal carcinoma and residual primary cancer. Dig Surg. 1998; 15(1):21-4. DOI: 10.1159/000018581. View